Vancouver, Canada

James Heyes

USPTO Granted Patents = 30 

 

 

Average Co-Inventor Count = 3.9

ph-index = 13

Forward Citations = 1,776(Granted Patents)


Location History:

  • Burnaby, CA (2010 - 2015)
  • Vancouver, CA (2010 - 2024)

Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
Loading Chart...
30 patents (USPTO):Explore Patents

Title: Innovator Spotlight: James Heyes - Pioneering Inventor Enhancing Therapeutic Delivery Systems

Introduction:

James Heyes, a distinguished inventor based in Vancouver, CA, has made significant contributions to the field of therapeutic delivery systems. With a remarkable portfolio of 27 patents, Heyes stands out as a visionary in developing targeted compositions and lipid formulations that revolutionize the treatment of various diseases, including cancer and hepatitis.

Latest Patents:

1. Targeted Compositions: Heyes' invention focuses on providing nucleic acids, particularly double-stranded siRNA molecules, along with conjugates containing a targeting moiety. These compositions are designed to effectively target therapeutic double-stranded siRNA to the liver, offering promising solutions for treating liver diseases such as hepatitis B and hepatitis D.

2. Lipid Formulations for Delivery of Therapeutic Agents: Heyes' innovative serum-stable lipid particles offer a novel approach to delivering active agents or therapeutic agents. By developing serum-stable nucleic acid-lipid particles (SNALP), Heyes has paved the way for the treatment of cancer through targeted lipid formulations that preferentially deliver payloads to solid tumor cells.

Career Highlights:

James Heyes has played a pivotal role in advancing therapeutic delivery systems through his work with prominent companies such as Protiva Biotherapeutics, Inc., and Arbutus Biopharma Corporation. His expertise and dedication have led to groundbreaking developments in the field, earning him recognition as a trailblazer in biomedical innovation.

Collaborations:

Throughout his career, Heyes has collaborated closely with esteemed professionals in the field, including colleagues like Ian MacLachlan and Mark Wood. This collaborative spirit has not only enriched Heyes' work but has also fostered a culture of innovation and excellence within the organizations he has been a part of.

Conclusion:

In summary, James Heyes' relentless pursuit of innovation and his groundbreaking work in developing targeted compositions and lipid formulations have significantly advanced the field of therapeutic delivery systems. His contributions have not only improved treatment outcomes for patients but have also set a new standard for excellence in biomedical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…